GLP-1 savings: which route fits your insurance?

A copay card reduces an eligible insurance claim. A self-pay offer sets a cash price outside insurance. A patient assistance program supplies an included medicine to people who meet its specific rules. Mixing these routes can leave you expecting a price you cannot receive.

We checked the linked manufacturer and CMS pages on October 1, 2026. We did not submit an application, test a pharmacy claim or verify any reader’s insurance eligibility. This is a comparison of published terms, not a promise of coverage or a recommendation to switch medicines. The official program links below are direct, not affiliate links.

Start with your coverage

Your situation	First route to check	What can prevent it working
Commercial insurance covers your prescribed medicine	Its manufacturer copay card	Benefit cap, deductible, excluded plan arrangement, prescription or presentation rules
Commercial plan excludes it	Product-specific noncovered offer or self-pay	A covered-drug card cannot create insurance coverage
Uninsured	Manufacturer cash price, then product-specific patient assistance	Income, residency and product eligibility differ
Medicare	Normal Part D coverage for a coverable indication, or eligible Medicare GLP-1 Bridge access	Commercial copay cards do not apply; Bridge is not open to everyone

Ask the pharmacy for the final amount under each eligible route before it dispenses the prescription. Keep the insurer’s rejection reason: missing prior authorization and an excluded benefit are different problems for your prescriber to address.

Covered commercial insurance: compare the caps

These are one-month covered-insurance offers. Longer fills and noncovered offers have different terms. Each link leads to the manufacturer’s eligibility rules.

Program	Advertised minimum	Maximum one-month benefit	Important boundary
Wegovy	$25	$100	Eligible commercial coverage; not a guaranteed $25 bill
Ozempic	$25	$100	Government beneficiaries excluded from the insured offer
Zepbound single-dose pen	$25	$100	Annual cap $1,300 and up to 13 fills; presentation matters
Mounjaro single-dose pen	$25	$150	Annual cap $1,950 and up to 13 fills; approved-use prescription required

Why a $25 offer can leave a $400 bill

Illustration, not an adjudicated claim: if an eligible covered prescription leaves you owing $500 and its card can reduce that by at most $100, you still owe at least $400. A card with a $150 cap would leave at least $350 in the same hypothetical situation. A $25 advertised floor does not remove the maximum-benefit limit. Annual exhaustion or other restrictions can leave you paying more.

Lilly defines a one-month single-dose-pen fill as 28 days and up to four pens. Do not multiply a 28-day quote by 12 and call it a full year’s uninterrupted supply. Compare the same days’ supply, presentation and indication. Having the same active molecule does not make two brands’ cards interchangeable.

Self-pay: compare the refill, not just the introduction

Wegovy’s published self-pay terms distinguish tablets from injections. Tablets are $149 at 1.5 mg, $199 at 4 mg and $299 at 9 mg or 25 mg. Eligible new injection patients pay $199 for each of two starter fills at 0.25 mg and 0.5 mg through December 31, 2026, then $349 for listed standard injection doses. The 7.2 mg HD injection is $399. These are different products and doses, not interchangeable shopping options.

For example, two eligible $199 starter fills followed by one $349 fill total $747, not $597. That arithmetic assumes the prescription and offer qualify and the stated terms remain available. Consultation charges are separate unless explicitly included.

Zepbound KwikPen’s published purchase offer lists $299 at 2.5 mg, $399 at 5 mg and a qualifying $449 offer at 7.5–15 mg. Continued eligibility for the higher-dose offer requires the refill purchase within 45 days of the previous delivery/receipt. Listed regular prices are $499 at 7.5 mg and $699 at 10–15 mg. At 10 mg, losing the $449 offer means a $250 difference before any extra charges. Check your presentation’s terms rather than applying KwikPen rules to a vial or single-dose pen.

These are budgeting examples, not instructions to change your dose or refill earlier than medically appropriate. NovoCare says self-pay spending does not count toward insurance deductible or out-of-pocket requirements and cannot be submitted for insurer reimbursement. Check how choosing cash affects your plan before switching payment routes.

Patient assistance: check the drug list first

Novo Nordisk’s PAP currently permits uninsured Ozempic patients with household income at or below 200% of the federal poverty level, subject to its other rules. Medicare beneficiaries with prescription drug coverage no longer qualify for Ozempic through this PAP. Other included medicines use a different income threshold. Do not treat the general Medicare/uninsured eligibility wording as overriding the Ozempic exception.

The Lilly Cares medication list does not list Mounjaro or Zepbound in this check. It does list Trulicity, but that is not permission to substitute it: the prescription, indication and assistance criteria must fit. A company’s assistance foundation is not a free-drug program for its entire catalog.

Medicare: Bridge is separate from Part D

CMS describes the GLP-1 Bridge as a temporary program through December 31, 2027 with a $50 copay for eligible beneficiaries. It operates outside the Part D payment flow. The Part D deductible does not apply, the $50 does not count toward Part D true out-of-pocket costs, and the low-income subsidy does not reduce this copay.

The CMS plan guidance lists Foundayo, Wegovy injections/tablets and Zepbound KwikPen for eligible weight-management use. Zepbound single-dose pens and vials are not included. People whose use is already coverable under Part D do not get to choose Bridge simply because its copay is lower. The provider guidance sets plan-type and clinical requirements and explains prior authorization. Ask your prescriber to check those criteria rather than assuming Medicare enrollment alone qualifies you.

Before filling: a short cost check

Write down the exact drug, presentation and days’ supply, the insurer’s coverage decision, the final pharmacy price after any card, remaining benefit/fill limits, and the next refill price. Compare the consultation fee too if you need a separate prescriber. Save the terms you relied on, since offers can change or end.

If the card rejects, ask the pharmacy to identify whether the problem is eligibility, exhausted benefit, prescription presentation or claim processing. Use the program’s help number rather than repeatedly enrolling for new cards.

If an approved drug is unaffordable, discuss available approved alternatives and assistance with your prescriber. FDA says compounded GLP-1 medicines are not FDA-approved and should be used only when an approved medicine cannot meet the patient’s medical need. A cheaper advertised compounded package is not an equivalent manufacturer savings program.